TARS vs. PRVL, FUSN, CABA, HARP, CBMG, CRSP, IBRX, KRYS, IMVT, and SWTX
Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Prevail Therapeutics (PRVL), Fusion Pharmaceuticals (FUSN), Cabaletta Bio (CABA), Harpoon Therapeutics (HARP), Cellular Biomedicine Group (CBMG), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), Krystal Biotech (KRYS), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "medical" sector.
Prevail Therapeutics (NASDAQ:PRVL) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.
Prevail Therapeutics received 4 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 64.62% of users gave Tarsus Pharmaceuticals an outperform vote while only 59.74% of users gave Prevail Therapeutics an outperform vote.
Tarsus Pharmaceuticals' return on equity of -55.57% beat Prevail Therapeutics' return on equity.
86.8% of Prevail Therapeutics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 57.2% of Prevail Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Tarsus Pharmaceuticals has a consensus target price of $50.38, suggesting a potential upside of 46.65%. Given Prevail Therapeutics' higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Prevail Therapeutics.
In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Prevail Therapeutics. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 0 mentions for Prevail Therapeutics. Prevail Therapeutics' average media sentiment score of 0.94 beat Tarsus Pharmaceuticals' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.
Prevail Therapeutics has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Prevail Therapeutics is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Prevail Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Summary
Tarsus Pharmaceuticals beats Prevail Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Tarsus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tarsus Pharmaceuticals Competitors List
Related Companies and Tools
